CapsoVision (CV) Stock Price, News & Analysis

Company Overview

CapsoVision develops medical technology for capsule endoscopy, a method of examining the digestive tract using a swallowable camera. Its products are designed to help clinicians visualize the small intestine as part of diagnostic evaluation.

The company’s CapsoCam Plus system uses a swallowable capsule with multiple cameras to capture panoramic images as it moves through the small intestine. Images are stored in the capsule and later retrieved for review using the company’s supporting hardware and software.

CapsoVision’s products serve healthcare providers in the United States and other markets. The company focuses on capsule-based imaging and related tools for viewing and managing examination data.

Key Stats

• Today's Range: $6.27 to $6.35
• 50-Day Range: $5.93 to $7.06
• 52-Week Range: $4.50 to $15.37
• Volume: 2,161 shs
• Average Volume: 231,375 shs
• Market Capitalization: $313.06 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.50
• Consensus Rating: Hold

CapsoVision Stock Analysis - MarketRank™

CapsoVision scored higher than 82% of companies evaluated by MarketBeat, and ranked 79th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Hold

Consensus Rating

CapsoVision has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

CapsoVision has a consensus price target of $9.50, representing about 51.5% upside from its current price of $6.27.

Amount of Analyst Coverage

CapsoVision has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for CapsoVision are expected to grow in the coming year, from ($0.56) to ($0.45) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of CapsoVision is -13.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of CapsoVision is -13.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

CapsoVision has a P/B Ratio of 22.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.99% of the float of CapsoVision has been sold short.

Short Interest Ratio / Days to Cover

CapsoVision has a short interest ratio ("days to cover") of 14.33, which indicates bearish sentiment.

Change versus previous month

Short interest in CapsoVision has recently decreased by 10.56%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CapsoVision does not currently pay a dividend.

Dividend Growth

CapsoVision does not have a long track record of dividend growth.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: 0.98

News Sentiment

CapsoVision has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for CapsoVision this week, compared to 2 articles on an average week.

Search Interest

3 people have searched for CV on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 3.7 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

2 insiders have purchased shares of CapsoVision in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $14,999,995.00 in company stock, which represents 4.7799% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, CapsoVision insiders have bought more of their company's stock than they have sold. Specifically, they have bought $14,999,995.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

2.30% of the stock of CapsoVision is held by insiders.

Percentage Held by Institutions

CapsoVision has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:CV
• CIK: 1378325
• Web: capsovision.com
• Phone: (408) 370-4790
• Fax: N/A
• Employees: 99
• Year Founded: 2005

Price Target and Rating

• Average Price Target for CapsoVision: $9.50
• High Price Target: $10.00
• Low Price Target: $9.00
• Potential Upside/Downside: +51.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.47)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$25.32 million
• Net Margins: -214.74%
• Pretax Margin: -214.56%
• Return on Equity: -177.85%
• Return on Assets: -135.07%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.35
• Quick Ratio: 2.44

Sales & Book Value

• Annual Sales: $13.55 million
• Price / Sales: 23.10
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.28 per share
• Price / Book: 22.34

Miscellaneous

• Outstanding Shares: 50,050,000
• Free Float: 48,896,000
• Market Cap: $313.06 million
• Optionable: N/A
• Beta: -2.34